Powering Pediatric Research and Innovation
AdventHealth for Children is creating the future of pediatric health care through research and data analysis to improve clinical performance and quality of care. Our nationally recognized children's hospital and network of pediatric specialists, programs and care facilities set the standard for innovation, quality and comprehensive care.
Rapid Whole Genome Sequencing
AdventHealth for Children is the first and only children's hospital in Central Florida to provide rapid whole genome sequencing, an advanced diagnostic technology, that will rapidly identify the causes of rare genetic disorders in some of the sickest infants and children.
Through a partnership with Rady Children’s Institute for Genomic Medicine, we are able to have access to a state-of-the-art genome sequencing lab that employs a multi-disciplinary team of experts who specialize in providing timely and accurate guidance to physicians caring for children with rare genetic disease. This partnership is the latest in AdventHealth's investment in genomics and will change the future of healthcare.
“Genomics is the future of medicine. This advanced testing can have a significant impact on how we diagnose and treat patients,. Rady Children’s Institute is a leader in genomic medicine, and this partnership will help us provide the best care to some of the littlest and sickest patients in our care.” - Dr. Rajan Wadhawan, Senior Executive Officer, AdventHealth for Children.
Highlighted Pediatrics Trials
Our goal at the Center for Pediatric Research is to create the future of pediatric health care through research and data analysis to improve clinical performance and quality of care. We seek to increase the ability of AdventHealth for Children to become a leading children’s network and to extend the healing ministry of Christ.
A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infant at Risk of Worsening Respiratory Distress Syndrome
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity
A Randomized, Open-Label, Active Controlled, Safety and Extrapolated Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event